About Elongin BC and Polycomb repressive complex 2-associated protein
Elongin BC and Polycomb repressive complex 2-associated protein (EPOP) is a protein
from Homo sapiens identified by UniProt accession
A6NHQ4, 379 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | Elongin BC and Polycomb repressive complex 2-associated protein |
| UniProt accession | A6NHQ4 |
| Gene | EPOP |
| Organism | Homo sapiens |
| Length | 379 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (30)
Diseases linked to this target (Open Targets).
- cortical surface area measurement · score 0.23
- chronic obstructive pulmonary disease · score 0.20
- appendicular lean mass · score 0.20
- peak expiratory flow · score 0.19
- forced expiratory volume · score 0.09
- leukocyte count · score 0.07
- vital capacity · score 0.05
- neuroticism measurement · score 0.05
- neutrophil count · score 0.04
- wellbeing measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NHQ4-F1 | alphafold | PREDICTED | 58.52 | — |
Amino-acid sequence (379 residues)
METLCPAPRL AVPASPRGSP CSPTPRKPCR GTQEFSPLCL RALAFCALAK PRASSLGPGP GELAARSPVL RGPQAPLRPG GWAPDGLKHL WAPTGRPGVP NTAAGEDADV AACPRRGEEE EGGGGFPHFG VRSCAPPGRC PAPPHPREST TSFASAPPRP APGLEPQRGP AASPPQEPSS RPPSPPAGLS TEPAGPGTAP RPFLPGQPAE VDGNPPPAAP EAPAASPSTA SPAPAAPGDL RQEHFDRLIR RSKLWCYAKG FALDTPSLRR GPERPPAKGP ARGAAKKRRL PAPPPRTAQP RRPAPTLPTT STFSLLNCFP CPPALVVGED GDLKPASSLR LQGDSKPPPA HPLWRWQMGG PAVPEPPGLK FWGINMDES
Explore Elongin BC and Polycomb repressive complex 2-associated protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets